(CDSCO) approves India’s first Chimeric Antigen Receptor (CAR)-T cell therapy to treat blood cancer
(CDSCO) approves India’s first Chimeric Antigen Receptor (CAR)-T cell therapy to treat blood cancer Therapy, called NexCAR19 (Actalycabtagene autoleucel) is the first humanized CD19-targeted CAR-T cell therapy. This therapy is…